Taiwan's Food and Drug Administration (FDA) on Tuesday (April 29) banned doctors from prescribing medicine containing any of four ingredients to people who have experienced an episode of sleepwalking or other movements while in a partially conscious state.
Eisai and Purdue Pharma have presented new clinical trial results of their dual orexin receptor antagonist lemborexant, which they think could become a new force in the sleep disorder market.
Research and Markets: China Sleep Disorder Treatment Drugs Markets Report 2015